Galderma announced that it has received a Positive Opinion from 16 concerned European regulatory agencies for the market approval of...
Galderma Laboratories announced that the FDA approved antibiotic-free Epiduo Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%, for the once-daily, topical...
Galderma has announced positive results from OSCAR, a phase IV trial, a multicenter, randomized, investigator-blinded, vehicle-controlled, intra-individual comparison study (right/left...
Epiduo 0.3% / 2.5% gel is indicated for the cutaneous treatment of Acne vulgaris , when comedones, numerous papules and pustules are present (see sections 4.2 and 5.1).
Cutaneous treatment of Acne vulgaris when comedones, papules and pustules are present (see section 5.1). Epiduo is indicated in adults, adolescents and children aged 9 years and over.
The FDA) has approved Bio-T-Gel, which is licensed by BioSante to Teva Pharmaceuticals USA, Inc. Bio-T-Gel is a testosterone gel...
Sol-Gel Technologies, Ltd. announced an update regarding the FDA approval process for Epsolay (benzoyl peroxide) 5% topical cream for the treatment of Inflammatory lesions of rosacea in adults. In September of 2020, Sol-Gel was informed by the FDA that the PDUFA goal date for Epsolay is April 26, 2021.